The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
about
Translation initiation factor eIF4F modifies the dexamethasone response in multiple myelomaThe Rapalogue, CCI-779, improves salivary gland function following radiation.Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain productionSC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathwayAn evolving role for DEPTOR in tumor development and progression.DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Future agents and treatment directions in multiple myeloma.Quercetin suppresses the proliferation of multiple myeloma cells by down-regulating IQ motif-containing GTPase activating protein 1 expression and extracellular signal-regulated kinase activation.Targeting the mTOR pathway in breast cancer.Poloxamer 188 Attenuates Cerebral Hypoxia/Ischemia Injury in Parallel with Preventing Mitochondrial Membrane Permeabilization and Autophagic Activation.mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein.VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma.
P2860
Q34218069-5E323042-CA36-4D5E-B209-00E386C8BC40Q35463371-127D34F1-63F6-49B3-A060-43D59B6DCB6CQ35664315-94F0FE9F-B622-46E1-9971-5F6732C4A343Q35761691-8DE8AADE-359C-4ADF-A723-C540747F572AQ36062133-A2E2C42B-E511-4986-9DE6-8EF12C4C3338Q37046569-6C4AD12D-6D2E-49D1-BDF0-D5CC08F81FF2Q38035044-725382B6-98A4-4E66-8656-BC89FE1F33B7Q38172300-CD483051-D6D3-40BF-803D-09C582184F5DQ39036817-7FF16813-6876-48A5-AE7C-1118C4C0429EQ39390640-C8093D4B-1186-450D-BBBA-06C272833A13Q40947659-AA0FBA12-CA5F-49E9-9D3C-741B26FF75ACQ42430902-F54991AF-2E5F-4AFA-9268-6E58013013C7Q47107700-ADF7C794-9345-4BD7-A8DD-F030C1747B46Q54112059-90910FF6-1771-40BA-B4FD-E76DBBBCF084
P2860
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@en
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@nl
type
label
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@en
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@nl
prefLabel
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@en
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@nl
P2860
P1433
P1476
The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma.
@en
P2093
Alan Lichtenstein
Joseph Gera
P2860
P304
P356
10.3109/10428194.2011.580478
P577
2011-05-23T00:00:00Z